Tag

treatment

5 minuti di lettura

Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS

(Adnkronos) – APDS (activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome) is a rare and progressive primary immunodeficiency Joenja® is a targeted treatment of APDS for adult and pediatric patients 12 years of age

Immediapress

Concept Medical granted Investigational Device Exemption (IDE) approval for their Magic Touch Sirolimus Coated Balloon for the treatment of Below the Knee (BTK) Arterial Disease

(Adnkronos) – TAMPA, Fla., Feb. 13, 2023 /PRNewswire/ — Concept Medical Inc. (CMI), on 9thFebruary 2023, received the Investigational Device Exemption (IDE) from the US FDA, for its Magic Touch Sirolimus Coated Balloon. The Magic Touch PTA Sirolimus Coated Balloon Catheter is

Investigational study provides evidence that recombinant endolysin XZ.700* is a promising novel non-antibiotic treatment strategy aimed at controlling Staphylococcus aureus (S. aureus) colonization of lesional skin in Cutaneous T-cell lymphoma (CTCL).

Immediapress

(Adnkronos) – Research shows XZ.700* could block tumor promoting effects of S. aureus on malignant T cells, potentially delaying tumor progression. Findings strengthen potential

Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma

Immediapress

(Adnkronos) – PARIS, May 10, 2023/PRNewswire/ — Servier, a global pharmaceutical group, today announced that the European Commission (EC) has approved Tibsovo® (ivosidenib tablets)

Octapharma to present clinical and scientific data that advances our understanding and treatment of bleeding disorders at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which takes place in Frankfurt, Germany, from February 6 – 9, 2024

mercoledì, 17 Gennaio 2024

Immediapress

(Adnkronos) – LACHEN, Switzerland, Jan. 17, 2024 /PRNewswire/ — Showcasing wilate® at EAHAD 2024 WIL-31 is the largest prospective prophylaxis study in VWD with an on-demand run-in study as an intra-individual

Octapharma to present clinical and scientific data that advances our understanding and treatment of bleeding disorders at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which takes place in Frankfurt, Germany, from February 6 – 9, 2024

mercoledì, 17 Gennaio 2024

Immediapress

International Collaboration to Improve Cancer Care in Sub-Saharan Africa Updates Resources for Sixth Year

mercoledì, 20 Dicembre 2023

Immediapress

(Adnkronos) – Collective effort to optimize and standardize treatment practices now covers more than 90% of adult cancer incidences plus an increasing number of pediatric diseases. PLYMOUTH MEETING, Pa., Dec. 20, 2023

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

lunedì, 13 Novembre 2023

Immediapress

(Adnkronos) – Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition ZUG, Switzerland and PARIS, Nov. 13, 2023

UZ Brussel PERT and Aidoc Pave the Way as First Hospital in Europe for Expedited Treatment of Pulmonary Embolism with AI

giovedì, 26 Ottobre 2023

Immediapress

(Adnkronos) – Aidoc AI identifies suspected cases of acute pulmonary embolism, enabling rapid care coordination and treatment cross-functionally with their PE Response Team LONDON, Oct. 26, 2023 /PRNewswire/ — Aidoc today announced

U.S. FDA GRANTS LIPOGEMS® SECOND IDE APPROVAL FOR A CLINICAL TRIAL ON THE TREATMENT FOR KNEE OA

mercoledì, 4 Ottobre 2023

Immediapress

(Adnkronos) – ATLANTA, Oct. 4, 2023 /PRNewswire/ — The U. S. Food and Drug Administration (FDA) has awarded Lipogems another Investigational Device Exemption (IDE) study for the use of MicroFat for the treatment

Englobe partners with OPTEL to ensure full global traceability of its contaminated soil treatment activities

lunedì, 2 Ottobre 2023

Immediapress

(Adnkronos) – QUEBEC, Oct. 2, 2023 /PRNewswire/ — Today, Englobe, the global pioneer in contaminated soil treatment and processing, announces its partnership with OPTEL to ensure full regulatory traceability of its soils

Advancing Cancer Treatment: Leo Cancer Care and THERYQ Collaborate on Innovative FLASHDEEP Patient Positioning

domenica, 1 Ottobre 2023

Immediapress

(Adnkronos) – PEYNIER, France, Oct. 1, 2023 /PRNewswire/ — The collaboration between Leo Cancer Care and THERYQ brings together the extensive expertise of both organizations to create an integrated solution that promises

Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection

venerdì, 14 Luglio 2023

Immediapress

(Adnkronos) – Topical treatment is achieving all endpoints for efficacy and safety in mild, moderate, and severe atopic dermatitis ANNAPOLIS, Md. and ASHEVILLE, N.C., July 14, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage

Study Proves iTind Treatment for Enlarged Prostate Lasts More than Four Years

giovedì, 13 Luglio 2023

Immediapress

(Adnkronos) – HAMBURG, Germany, July 13, 2023 /PRNewswire/ — Olympus Corporation, a global medical technology company, announced publication of study data demonstrating that the minimally invasive iTind™ treatment provides long-lasting relief of more than

1 2 Avanti

treatment

Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS

Concept Medical granted Investigational Device Exemption (IDE) approval for their Magic Touch Sirolimus Coated Balloon for the treatment of Below the Knee (BTK) Arterial Disease

Investigational study provides evidence that recombinant endolysin XZ.700* is a promising novel non-antibiotic treatment strategy aimed at controlling Staphylococcus aureus (S. aureus) colonization of lesional skin in Cutaneous T-cell lymphoma (CTCL).

Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma

Octapharma to present clinical and scientific data that advances our understanding and treatment of bleeding disorders at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which takes place in Frankfurt, Germany, from February 6 – 9, 2024

Octapharma to present clinical and scientific data that advances our understanding and treatment of bleeding disorders at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which takes place in Frankfurt, Germany, from February 6 – 9, 2024

International Collaboration to Improve Cancer Care in Sub-Saharan Africa Updates Resources for Sixth Year

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

UZ Brussel PERT and Aidoc Pave the Way as First Hospital in Europe for Expedited Treatment of Pulmonary Embolism with AI

U.S. FDA GRANTS LIPOGEMS® SECOND IDE APPROVAL FOR A CLINICAL TRIAL ON THE TREATMENT FOR KNEE OA

Englobe partners with OPTEL to ensure full global traceability of its contaminated soil treatment activities

Advancing Cancer Treatment: Leo Cancer Care and THERYQ Collaborate on Innovative FLASHDEEP Patient Positioning

Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection

Study Proves iTind Treatment for Enlarged Prostate Lasts More than Four Years

Primo piano

CdM approva decreto urgente per autotrasporto, agricoltura e pesca. Meloni: “Non tolleriamo intimidazioni” | Video

Il prete che ha mostrato il dito medio ai ragazzi durante i disordini a Milano: «Pentito? No, ho solo risposto»

Italia-Spagna, la sospensione di Schengen non sarà rinnovata

Blocco Tir, governo “sblocca” in Sicilia e Calabria, ma il Golfo di Napoli a rischio isolamento

Dopo gli scontri: cosa prevede il decreto e quali poteri hanno i militari

Sponsor

Suggerimenti

treatment

Primo piano

Sponsor